



Audaire Health Cell and Gene Therapy (CGT) Outcomes Tracking Program Frequently Asked Questions for providers Ohio Market (Medicaid, Medicare, Marketplace)

Table of Contents

What is the CareSource Audaire Health™ CGT outcomes tracking program?	1
Why is CareSource implementing the Audaire Health™ Provider Portal?	2
Which therapies will be tracked in the Audaire Health™ Provider Portal?	2
Who does this program apply to?	2
How will patients be added to the Audaire Health™ Provider Portal?	2
When and how should providers submit outcomes to Audaire Health™?	3
What information is entered in the Audaire Health™ portal?	3
How should you prepare for this change?	3
What action should providers take after November 1, 2025?	4
What if the patient does not receive the approved therapy?	4
How long will clinical outcomes be tracked on the Audaire Health™ Provider Portal?	4
Will this program change the current prior authorization process for cell and gene therapy?	4
Who should providers contact for questions regarding the CareSource Audaire Health™ CGT Outcomes Tracking Program?	4

What is the CareSource Audaire Health™ CGT outcomes tracking program?

Beginning November 1, 2025, CareSource will require providers who administer select cell and gene therapies to submit clinical outcomes data through the Audaire Health™ provider portal for Ohio members.

This program supports value-based care by improving how treatment effectiveness is tracked. It helps reduce administrative burden, ensures more complete data capture for these therapies, and provides insights that help CareSource better understand how cell and gene therapies perform in the real world.

Why is CareSource implementing the Audaire Health™ Provider Portal?

CareSource is implementing the Audaire Health™ provider portal to collect and assess the clinical benefits of these therapies. The portal will streamline the process for submitting patient information and related outcomes data.

By replacing manual processes with a streamlined electronic system, the portal helps save time by reducing paperwork and easing the administrative burden on your staff. It also helps cut down on back-and-forth phone calls, freeing up your team to focus more on patient care.

Which therapies will be tracked in the Audaire Health™ Provider Portal?

The following therapies will be tracked in the Audaire Health™ provider portal. As additional therapies are added, the list below will be updated, and a network notification will be published.

PROCEDURE CODE	BRAND NAME	GENERIC NAME	EFFECTIVE DATE
Q2055	ABECMA	Idecabtagene vicleucel	11/01/2025
Q2058	AUCATYZL	Obecabtagene autoleucel	11/01/2025
Q2054	BREYANZI	Lisocabtagene maraleucel	11/01/2025
Q2056	CARVYKTI	Ciltacabtagene autoleucel	11/01/2025
Q2042	KYMRIAH	Tisagenleucel	11/01/2025
Q2053	TECARTUS	Brexucabtagene autoleucel	11/01/2025
Q2041	YESCARTA	Axicabtagene ciloleucel	11/01/2025

Who does this program apply to?

The CareSource Audaire Health™ CGT outcomes tracking program applies to CareSource Ohio members (Medicaid, MyCare, D-SNP, and Marketplace) who receive any included cell or gene therapy on or after November 1, 2025.

How will patients be added to the Audaire Health™ Provider Portal?

Once a patient is approved for a specific cell or gene therapy, an Audaire Health™ representative will contact your clinic or outpatient facility by phone or email to collect initial information.

The patient's demographic details will be added to the Audaire Health™ provider portal for you. When it's time to report outcomes, your staff will receive an email from hello@audaire.com with a secure link to complete the portal survey.

When and how should providers submit outcomes to Audaire Health™?

Audaire Health™ will contact your clinic approximately 3 months after the targeted cell or gene therapy prior authorization expires to confirm whether the therapy was administered.

As part of the approval process, providers must attest that they will submit clinical outcomes data using the Audaire Health™ provider portal.

Outcomes data can be submitted in one of three ways:

- Online via the provider portal: <https://www.audaire.com/portal>
- By phone or fax with an Audaire Health™ representative

Designated representatives, such as pharmacists, nurses, medical assistants, or other clinical support staff, may submit outcomes on behalf of the provider.

What information is entered in the Audaire Health™ portal?

When reporting outcomes data in the Audaire Health™ provider portal, you will use the drop-downs and free-text fields to enter information about the patient's/member's clinical response to therapy. You will also use this survey to document any adverse events following administration of the therapy. It takes approximately 5 minutes to complete the survey.

How should you prepare for this change?

You do not need to take any immediate action.

When CareSource first approves a prior authorization request you submitted for one of the specified therapies, an Audaire Health™ representative will contact you to schedule a 15-minute phone call. During this call, the representative will:

- Create your Audaire Health™ profile (which completes your attestation)
- Provide training on how to use the Audaire Health™ provider portal
- Answer any questions you have about the portal

Note: If you already have patients with active CareSource coverage for whom an authorization request was approved before November 1st, an Audaire representative will also reach out to you.

What action should providers take after November 1, 2025?

No immediate action is required when the CareSource CGT outcomes tracking program launches on November 1, 2025.

If a patient is approved for a specified cell or gene therapy, an Audaire Health™ representative will contact your facility approximately 3 months after the prior authorization expiration to confirm whether the therapy was administered.

What if the patient does not receive the approved therapy?

If the approved therapy is not administered, CareSource will still add the patient's demographic information to the Audaire Health™ provider portal and indicate that therapy was not given. No outcomes will be required in this case.

How long will clinical outcomes be tracked on the Audaire Health™ Provider Portal?

For patients who receive specified cell or gene therapy, providers will be asked to submit clinical outcomes at the following intervals after CGT administration:

- 3 months
- 6 months
- 12 months
- 24 months

Will this program change the current prior authorization process for cell and gene therapy?

No, this program will not affect the existing prior authorization process.

For CAR-T and all oncology therapies, providers should continue submitting prior authorization requests through the NantHealth/Eviti Connect portal, as usual. For all other cell and gene therapies, continue submitting prior authorization requests to CareSource electronically or via fax.

Who should providers contact for questions regarding the CareSource Audaire Health™ CGT Outcomes Tracking Program?

Please direct all questions to: CareSource Ohio Pharmacy
(caresourceohrx@caresource.com)